

Please type a plus sign (+) inside this box

Attorney Docket P1014R1C1D1C1  
PATENT

EV 351932786 US: Express Mail Numbr r

September 19, 2003: Date of Deposit

22141 U.S. PTO  
10/665658  
  
09/19/03

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Mail Stop PATENT APPLICATION  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

NON-PROVISIONAL APPLICATION TRANSMITTAL UNDER 37 CFR 1.53(b)

Transmitted herewith for filing is a non-provisional patent application:

Inventor(s) (or Application "Identifier"):

Paula M. Jardieu, Utica, New York  
Leonard G. Presta, San Francisco, California

Title: Method of Treatment Using Humanized Anti-CD11a Antibodies

1. Type of Application

- This application is for an original, non-provisional application.
- This is a non-provisional application claiming priority to provisional application no. \_\_, filed \_\_\_, the entire disclosure of which is hereby incorporated by reference.
- This is a  continuation-in-part  continuation  divisional application claiming priority to application Serial Number 09/795,798, filed February 28, 2001, which is a divisional of application Serial Number 09/420,745, filed October 20, 1999 (now abandoned), which is a continuation of application Serial Number 08/974,899, filed November 20, 1997 (U.S. Patent Number 6,037,454), which claims benefit of 60/031,971, filed November 27, 1996, the entire disclosures of which are hereby incorporated by reference.

2. Papers Enclosed Which Are Required For Filing Date Under 37 CFR 1.53(b)

(Non-provisional )

- 99 pages of specification  
2 pages of claims  
1 page(s) of abstract  
4 sheet(s) of drawings  
 formal  informal

3. Declaration or Oath

(for new and CIP applications; also for Cont./Div. where inventor(s) are being added)  
An executed declaration of the inventor(s)  is enclosed  will follow.

*(for Cont./Div. where inventorship is the same or inventor(s) being deleted)*

- A copy of the executed declaration/oath filed in the prior application is enclosed (37 CFR 1.63(d)).

*(for Cont./Div. where inventor(s) being deleted)*

- A signed statement is attached deleting inventor(s) named in the prior application (see 37 CFR 1.63(d)(2) and 1.33(b)).

#### 4. Assignment

*(for new and CIP applications)*

- An Assignment of the invention to GENENTECH, INC. [] is enclosed with attached Recordation Form Cover Sheet [] will follow.

*(for cont./div.)*

- The prior application is assigned of record to Genentech, Inc.

#### 5. Amendments **(for continuation and divisional applications)**

- Cancel in this application original claims \_\_\_ of the prior application before calculating the filing fee. (At least one original independent claim must be retained for filing purposes.)
- A preliminary amendment is enclosed. (Claims added by this amendment have been properly numbered consecutively beginning with the number next following the highest numbered original claim in the prior application.)

#### 6. Fee Calculation (37 CFR 1.16)

The fee has been calculated as follows:

<b>CLAIMS FOR FEE CALCULATION</b>					
Number Filed		Number Extra		Rate	Basic Fee 37 CFR 1.16(a)
					\$750.00
Total Claims	14	- 20 =	0	X \$18.00	\$0.00
Independent Claims	2	- 3 =	0	X \$84.00	\$0.00
Multiple dependent claim(s), if any				+ \$280.00	\$0.00
<b>Filing Fee Calculation</b>					\$750.00

#### 7. Method of Payment of Fees

The Commissioner is hereby authorized to charge Deposit Account No. 07-0630 in the amount of \$750.00. **A duplicate copy of this transmittal is enclosed.**

**8. Authorization to Charge Additional Fees**

The Commissioner is hereby authorized to charge any additional fees required under 37 CFR §1.16 and 1.17, or credit overpayment to Deposit Account No. 07-0630. A duplicate copy of this transmittal is enclosed.

**9. Additional Papers Enclosed**

- Information Disclosure Statement (37 CFR §1.98) w/ PTO-1449 and citations  
 Submission of "Sequence Listing", computer readable copy, certificate re: sequence listing, and/or amendment pertaining thereto for biological invention containing nucleotide and/or amino acid sequence.  
 A new Power of Attorney or authorization of agent.  
 Other: Application Data Sheet

**10. Maintenance of Copendency of Prior Application (for continuation and divisional applications)**

*[This item must be completed and the necessary papers filed in the prior application if the period set in the prior application has run]*

- \_\_\_\_\_ A petition, fee and/or response has been filed to extend the term in the pending prior application until  
\_\_\_\_\_ A copy of the petition for extension of time in the **prior** application is attached.

**11. Correspondence Address:**

- Address all future communications to:

Attn: Lee K. Tan, Ph.D.  
Customer No: 09157

Respectfully submitted,  
GENENTECH, INC.

Date: September 19, 2003

By: Lee Tan  
Lee K. Tan, Ph.D.  
Reg. No. 39,447  
Telephone No. (650) 225-4462

**CUSTOMER NO: 09157**